Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Price

ACRVStock
$2.18+61.76%52W
Market Cap$93.42M
P/E
PEG Ratio
Div yield
Beta1.94

ACRV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)27.12%
Price vs S&P 500 (4W)39.81%
VGM Score78.79

ACRV Earnings Surprise History

Q2 25-0.55est. -0.58
Q3 25-0.47est. -0.58
Q4 25-0.49est. -0.46
Q1 26-0.49est. -0.52
Q2 26-0.43est. -0.50

ACRV Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.21
4.21
4.21
4.21

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ACRVAcrivon Therapeutics, Inc. Common Stock
B$2.18
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncology medicines paired with a proprietary proteomics platform designed to identify patients most likely to respond to treatment. Its lead program, prexasertib (ACR-368), is in Phase 2 development. The preclinical pipeline targets DNA damage response and cell cycle regulation pathways.